Document text
BioNTech SE 06/30/2021
An der Goldgrube 12
Mainz N/A
Germany 55131215-280-5503
COVID-19 Vaccine (BNT162, PF-07302048) 019736
Active immunization to prevent COVID-19 caused by
SARS-CoV-2
Phase 4
BB-IND 013812, BB-IND 013278, BLA 125549
0 3 8 6
3
FDA-CBER-2021 5683-1072501
Özlem Türeci, MD, Chief Medical Officer, BioNTech SE
Özlem Türeci, MD, Chief Medical Officer, BioNTech SE
Neda Aghajani Memar, Pharm.D., Director, Pfizer Global Regulatory Affairs - Vaccines
212-733-2613 (845) 474-3500
235 East 42nd Street
219/9/69
New York NY
United States of America [email protected]
06/29/2021
United States of America
Neda Aghajani
MemarDigitally signed by Neda Aghajani Memar
DN: cn Neda Aghajani Memar, o, ou,
email [email protected], c US
Reason: I attest to the accuracy and integrity of this
document
Date: 2021.06.29 15:45:07 -04'00'
3
FDA-CBER-2021-5683-1072502
3
FDA-CBER-2021-5683-1072503